BIOPHARMA
By
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
Could GSK and Hengrui’s $12B Alliance Set a New Standard in China-Originated Drug Collaborations?
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…
